The global market for erectile dysfunction drugs from $ 5.7 billion by 2023

Dublin, 16 February 2021 (GLOBE NEWSWIRE) – The report “Drugs for Erectile Dysfunction in the Global Market 2020-30: COVID-19 Performance and Recovery” has been added in ResearchAndMarkets.com’s offer.

The global market for erectile dysfunction drugs is expected to fall from $ 5 billion in 2019 to $ 3.4 billion in 2020 at a compound annual growth rate (CAGR) of -32.5%. The decline is mainly due to disruption caused by the locking measure in various countries to combat the spread of COVID-19.

The market for erectile dysfunction (ED) drugs consists of the sale of erectile dysfunction (ED) drugs and related services. Erectile dysfunction is the inability to achieve or maintain an erection of the penis in men.

There is currently less demand for genito-urinary drugs, mainly because people stay at home and less exposure to factors that can cause genito-urinary tract infections or other hormonal diseases caused by lifestyle changes or eating habits. The market is then expected to recover and grow by 3.7% from 2021 CAGR and reach $ 5.7 billion in 2023.

The market for erectile dysfunction drugs is geographically segmented into North America, Western Europe, APAC, Eastern Europe, South America, and the Middle East and Africa. The North American market is the largest market for erectile dysfunction drugs and is expected to continue to be the largest market over the forecast period.

A drastic increase in the number of chronic diseases is driving the market for drugs for erectile dysfunction. Erectile dysfunction is mainly caused by chronic diseases that result from an inactive lifestyle such as cardiovascular disease, diabetes, obesity and high blood pressure. According to the WHO, the prevalence of chronic diseases is expected to increase by 57% by the end of 2020. The prevalence of chronic diseases increases the chances of erectile dysfunction among men, and thus launches the market for drugs for erectile dysfunction.

Patients suffering from erectile dysfunction do not seek treatment due to factors such as lack of education, lack of awareness, strong religious beliefs, social taboos, and low socioeconomic status. These factors are responsible for patients suffering from erectile dysfunction refusing or avoiding treatment. For example, a study conducted by Harlem Hospital in New York in 2018 among 100 men found that more than 86% of respondents had no knowledge that smoking causes erectile dysfunction. These factors are holding back the growth of the market for erectile dysfunction drugs.

Many companies in the market for erectile dysfunction drugs are applying new drug delivery techniques, such as the use of pellets and creams. Pellets and creams will have greater efficiency and performance in erectile dysfunction, and are also more effective and safer to use. These benefits of drug delivery techniques will increase the scope of the erectile dysfunction drug market. For example, in 2018, Apricus Biosciences entered the production of a cream called vitaros for the treatment of erectile dysfunction.

Regulators approve medicines on the basis of quality, safety and efficacy to ensure that medicines are of standard quality and provide positive benefits. Companies are authorized to submit standard quality documentation before applying for approval.

The safety and efficacy of drugs should be demonstrated by companies in clinical trials for all new drugs. The competent authorities will assess this information before approving medicines. In Europe, the European Medicines Agency (EMA) evaluates medicines for centrally authorized products.

Major market players are Eli Lilly and Co., Pfizer, Bayer AG, Dong-A Pharmaceutical Co. Ltd and Vivus.

Key topics:

1. Summary

2. Characteristics of the erectile dysfunction drug market

3. The size and growth of the market for erectile dysfunction drugs
3.1. Global Erectile Dysfunction Drugs Historical Market, 2015-2019, $ billion
3.1.1. Market drivers
3.1.2. Market restrictions
3.2. Global Erectile Dysfunction Drug Market, 2019-2023F, 2025F, 2030F, $ billion
3.2.1. Market drivers
3.2.2. Market restrictions

4. Drugs for Erectile Dysfunction Market segmentation
4.1. Global drugs for erectile dysfunction market, drug segmentation, history and forecast, 2015-2019, 2023F, 2025F, 2030F, billion dollars

  • Sildenafil citrate

  • Mirodenafil

  • Vardenafil

  • Tadalafil

  • Udenafil

  • Stand / Spedra

  • Lodenafil carbonate

4.2. Global market for erectile dysfunction drugs, end-user segmentation, past and forecast, 2015-2019, 2023F, 2025F, 2030F, billion dollars

  • Hospital pharmacies

  • Retail pharmacies

  • Internet pharmacies

4.3. Global market for erectile dysfunction drugs, segmentation by mode of administration, past and forecast, 2015-2019, 2023F, 2025F, 2030F, billion dollars

5. Regional market analysis and drugs for erectile dysfunction
5.1. Global market for erectile dysfunction drugs, divided by regions, history and forecast, 2015-2019, 2023F, 2025F, 2030F, billion dollars
5.2. Global drugs for erectile dysfunction market, broken down by country, history and forecast, 2015-2019, 2023F, 2025F, 2030F, billion dollars

Mentioned companies

  • Eli Lilly and Co.

  • Pfizer

  • Bayer AG

  • Dong-A Pharmaceutical Co. Ltd.

  • Vivus

  • Meda Pharmaceuticals

  • Apricus Biosciences

  • Crystal

  • SK Chemicals Co

  • Teva Pharmaceutical Industries Ltd.

  • Products Chemicals Pharmaceuticals Ltd.

  • Johnson & Johnson Services

  • Bonro Medical

  • Post-T-Vac Medical

  • Augusta Medical Systems LLC (Augusta Medical)

  • Zephyr Surgical Implants (ZSI)

  • Premedon

  • Futura Medical

  • Endo International plc

  • Coloplast A / S

  • Boston Scientific Corp

  • Seelos Therapeutics

For more information on this report visit https://www.researchandmarkets.com/r/tbqq0l

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Source